[S8] シンポジウム8「癌」

[S8-2] Clinical trials and next-generation technology development of Survivin-responsive conditionally replicating adenovirus targeting and treating with multiple factors (Surv.m-CRA)

^○Ken-ichiro Kosai^1,2, 永野 聡^1,2,3 (1.Kagoshima University Graduate School of Medical and Dental Sciences / Kagoshima University Hospital, 2.鹿児島大学病院, 3.鹿児島大学医学部保健学科)

キーワード：Oncolytic virus immunotherapy, Vector development, Regenerative medicine, Stem cell biology, Growth factor (biology and application), Translational research

1988        Resident (Pediatrics) and Graduate Student (Pathology), Kurume University School of Medicine
1992        Assistant Professor, Department of Pathology, Kurume University School of Medicine
1993        Post Doc.> Visiting Assistant Professor (1994-), Baylor Collage of Medicine, USA
1996        Visiting Assistant Professor, Division of Biochemistry, Osaka University Medical School
1997        Assistant Professor, Kurume University Research Center for Innovative Cancer Therapy, (and Departments of Pediatrics, Human Genetics and Surgery), Kurume University
2000        Associate Professor, Department of Gene Therapy and Regenerative Medicine, Gifu University School of Medicine
2003        Professor, Cognitive and Molecular Research Institute for Brain Diseases, (and Department of Pediatrics), Kurume University
2006        Professor and Chairman, Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medicine and Dental Sciences
 
(Secondary appointment)
Director, South Kyushu Center for Innovative Medical Research and Application,
Director, Center for Innovative Therapy Research and Application,
Kagoshima University Graduate School of Medicine and Dental Sciences
Director, Center for Clinical and Translational Research, Kagoshima University Hospital
Visiting Faculty, Kurume University School of Medicine
Founder, President and Chief Scientific Officer, SurvBiopharma Inc.
Advisory Board Member, Biologics Center for Research and Training